Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

Cancer letters - 8 Sept 2007

Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack P C, Gumerlock P H, Kung H J, Stahel R A, Gandara D R, Betticher D C

Abstract excerpt

Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Restriction Fragment Length

Share to Prognosis

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Analysis

Source

Identifiers

PMID: 17449174
DOI: 10.1016/j.canlet.2007.03.008

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Origin and prognostic value of circulating KRAS mutations in lung cancer patients.PMID 17449174Read ↗

Potential Clinical Significance of a Plasma-Based <i>KRAS</i> Mutation Analysis in Patients with Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Prognostic value of specific KRAS mutations in lung adenocarcinomas.Semantic proximity Read ↗

Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.Semantic proximity Read ↗

KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.Semantic proximity Read ↗

High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer.Semantic proximity Read ↗

KRAS codon 12 mutations in Australian non-small cell lung cancer.Semantic proximity Read ↗

Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma.Semantic proximity Read ↗

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.Semantic proximity Read ↗

K-ras codon 12 mutations may be detected in serum of patients suffering from adeno- and large cell lung carcinoma. A preliminary report.Semantic proximity Read ↗

Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.Semantic proximity Read ↗

ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.